X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24669) 24669
Newsletter (730) 730
Book Chapter (41) 41
Dissertation (41) 41
Newspaper Article (25) 25
Publication (13) 13
Conference Proceeding (12) 12
Magazine Article (10) 10
Transcript (6) 6
Book Review (4) 4
Government Document (4) 4
Web Resource (4) 4
Report (3) 3
Journal / eJournal (2) 2
Paper (2) 2
Streaming Video (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19073) 19073
etoposide (11606) 11606
male (10395) 10395
oncology (10088) 10088
female (10026) 10026
etoposide - administration & dosage (9243) 9243
antineoplastic combined chemotherapy protocols - therapeutic use (9158) 9158
adult (7626) 7626
middle aged (7573) 7573
chemotherapy (6791) 6791
aged (5416) 5416
cancer (4819) 4819
cisplatin - administration & dosage (4074) 4074
etoposide - pharmacology (4025) 4025
treatment outcome (3625) 3625
cisplatin (3524) 3524
antineoplastic combined chemotherapy protocols - adverse effects (3208) 3208
adolescent (3176) 3176
combined modality therapy (3074) 3074
hematology (3054) 3054
lung neoplasms - drug therapy (2952) 2952
cyclophosphamide - administration & dosage (2858) 2858
animals (2811) 2811
etoposide - therapeutic use (2712) 2712
apoptosis (2630) 2630
antineoplastic combined chemotherapy protocols - administration & dosage (2459) 2459
etoposide - adverse effects (2397) 2397
doxorubicin - administration & dosage (2335) 2335
prognosis (2323) 2323
vincristine - administration & dosage (2186) 2186
child (1955) 1955
survival rate (1912) 1912
therapy (1892) 1892
drug administration schedule (1834) 1834
remission induction (1787) 1787
carboplatin - administration & dosage (1762) 1762
neoplasm staging (1704) 1704
apoptosis - drug effects (1693) 1693
cyclophosphamide (1684) 1684
retrospective studies (1677) 1677
care and treatment (1664) 1664
survival analysis (1657) 1657
mice (1651) 1651
disease-free survival (1607) 1607
research (1601) 1601
pharmacology & pharmacy (1587) 1587
carboplatin (1562) 1562
carcinoma, small cell - drug therapy (1530) 1530
tumors (1511) 1511
child, preschool (1510) 1510
dose-response relationship, drug (1460) 1460
antineoplastic agents - pharmacology (1423) 1423
bleomycin - administration & dosage (1409) 1409
biochemistry & molecular biology (1404) 1404
cytarabine - administration & dosage (1404) 1404
cell line, tumor (1394) 1394
survival (1391) 1391
follow-up studies (1374) 1374
ifosfamide - administration & dosage (1358) 1358
carcinoma (1346) 1346
transplantation (1278) 1278
doxorubicin (1273) 1273
lung neoplasms - pathology (1215) 1215
time factors (1202) 1202
tumor cells, cultured (1199) 1199
expression (1185) 1185
radiotherapy (1184) 1184
dna damage (1183) 1183
cell biology (1167) 1167
aged, 80 and over (1127) 1127
infant (1124) 1124
antineoplastic agents - therapeutic use (1123) 1123
trial (1102) 1102
methotrexate - administration & dosage (1046) 1046
antineoplastic agents, phytogenic - pharmacology (1026) 1026
analysis (984) 984
children (983) 983
salvage therapy (981) 981
combination chemotherapy (974) 974
pediatrics (960) 960
ifosfamide (953) 953
medicine & public health (945) 945
transplantation, autologous (944) 944
recurrence (941) 941
phase-ii (932) 932
young adult (932) 932
prednisone - administration & dosage (916) 916
cisplatin - adverse effects (896) 896
carcinoma, non-small-cell lung - drug therapy (891) 891
leukemia (882) 882
lung cancer (874) 874
prospective studies (870) 870
drug resistance, neoplasm (860) 860
testicular neoplasms - drug therapy (858) 858
surgery (848) 848
hematopoietic stem cell transplantation (847) 847
toxicity (830) 830
lung neoplasms - mortality (820) 820
drug resistance (812) 812
cell survival - drug effects (811) 811
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (23808) 23808
Japanese (1135) 1135
German (285) 285
French (280) 280
Chinese (243) 243
Spanish (102) 102
Russian (93) 93
Polish (55) 55
Italian (46) 46
Korean (33) 33
Portuguese (25) 25
Hungarian (20) 20
Czech (14) 14
Dutch (9) 9
Turkish (9) 9
Serbian (8) 8
Hebrew (6) 6
Croatian (3) 3
Danish (2) 2
Norwegian (2) 2
Romanian (2) 2
Swedish (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Indonesian (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biomarker research, ISSN 2050-7771, 12/2019, Volume 7, Issue 1, pp. 1 - 1
The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoprostate cancer using magnetic... 
Etoposide
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2011, Volume 333, Issue 6041, pp. 459 - 462
Journal Article
British Journal of Haematology, ISSN 0007-1048, 04/2015, Volume 169, Issue 2, pp. 188 - 198
Summary This prospective multi‐institutional phase II study was designed to assess the efficacy and safety of dose‐adjusted EPOCH (etoposide,... 
vincristine | and rituximab | large B‐cell lymphoma | cyclophosphamide | doxorubicin | dose‐adjusted‐EPOCH‐R (etoposide, prednisone | high‐risk patients | cell of origin | Dose-adjusted-EPOCH-R (etoposide, prednisone | Cyclophosphamide | And rituximab | Cell of origin | Large B-cell lymphoma | High-risk patients | Doxorubicin | Vincristine | SURVIVAL | DLBCL | BCL-2 GENE | REGIMEN | GERMINAL CENTER | CHEMOTHERAPY | high-risk patients | large B-cell lymphoma | PROTEIN EXPRESSION | dose-adjusted-EPOCH-R (etoposide | NON-HODGKINS-LYMPHOMA | CHOP | TISSUE MICROARRAY | prednisone | HEMATOLOGY | Doxorubicin - therapeutic use | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Neoplasm Grading | Adult | Female | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Rituximab | Etoposide - therapeutic use | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Medical research | Anthracyclines | Corticosteroids | Analysis | Clinical trials | Medicine, Experimental | Etoposide | Lymphomas | Prednisone | Index Medicus
Journal Article
Journal Article
EXCLI Journal, 01/2015, Volume 14, pp. 95 - 108
Journal Article
Nature medicine, ISSN 1546-170X, 2006, Volume 13, Issue 1, pp. 54 - 61
Anthracyclin-treated tumor cells are particularly effective in eliciting an anticancer immune response, whereas other DNA-damaging agents such as etoposide and... 
MEDICINE, RESEARCH & EXPERIMENTAL | CLEARANCE | DENDRITIC CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUMOR | CHAPERONE | CELL BIOLOGY | DYING CELLS | APOPTOTIC CELLS | SURFACE CALRETICULIN | ENDOPLASMIC-RETICULUM | BINDING | ANTIGEN | Apoptosis - drug effects | Colonic Neoplasms - drug therapy | Dendritic Cells - immunology | Electrophoresis, Gel, Two-Dimensional | Immunoblotting | Antineoplastic Agents - therapeutic use | Protein Transport - drug effects | Calreticulin - genetics | Colonic Neoplasms - metabolism | Cell Cycle Proteins - antagonists & inhibitors | RNA Interference | Anthracyclines - pharmacology | Neoplasms, Experimental - immunology | Calreticulin - metabolism | Antigens, Differentiation - metabolism | Antineoplastic Agents - pharmacology | Cell Membrane - metabolism | Protein Phosphatase 1 | Cell Membrane - drug effects | Mitomycin - therapeutic use | Cell Cycle Proteins - metabolism | Phagocytosis - immunology | Etoposide - pharmacology | Etoposide - therapeutic use | Recombinant Proteins - pharmacology | Mitomycin - pharmacology | Animals | Apoptosis - immunology | Mice, Nude | Colonic Neoplasms - pathology | Cell Line, Tumor | Cell Membrane - immunology | Mice | Mice, Inbred BALB C | Anthracyclines - therapeutic use | Calreticulin - immunology | Neoplasms, Experimental - metabolism | Neoplasms, Experimental - drug therapy | Chemotherapy | Immunology | DNA damage | Rodents | Cancer | Apoptosis | Tumors | Antigens, Differentiation | Cell Membrane | Anthracyclines | Dendritic Cells | Recombinant Proteins | Life Sciences | Calreticulin | Neoplasms, Experimental | Mitomycin | Etoposide | Antineoplastic Agents | Protein Transport | Phagocytosis | Cell Cycle Proteins | Colonic Neoplasms
Journal Article
Journal Article
Journal Article
Journal of Cell Science, ISSN 0021-9533, 03/2012, Volume 125, Issue 6, pp. 1568 - 1578
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2011, Volume 103, Issue 19, pp. 1452 - 1460
Background The combination of chemotherapy with thoracic radiotherapy (TRT) compared with TRT alone has been shown to confer a survival advantage for good... 
IRRADIATION | CARBOPLATIN | CISPLATIN | VINORELBINE | ONCOLOGY | THERAPY-ONCOLOGY-GROUP | CHEMORADIOTHERAPY | RADIOTHERAPY | CHEMOTHERAPY | RADIATION-THERAPY | PACLITAXEL | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - radiotherapy | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Time Factors | Vinblastine - adverse effects | Aged, 80 and over | Adult | Dose Fractionation | Chemotherapy, Adjuvant | Odds Ratio | Radiotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung - pathology | Radiotherapy Dosage | Etoposide - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Etoposide - administration & dosage | Treatment Outcome | Disease Progression | Canada | Confounding Factors (Epidemiology) | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Etoposide | Research | Lung cancer, Non-small cell | Drug therapy | Radiotherapy | Health aspects | Index Medicus
Journal Article
Acta Biomaterialia, ISSN 1742-7061, 01/2016, Volume 29, pp. 320 - 332
[Display omitted] Etoposide (VP16), used for the treatment of many carcinomas, can cause leukopenia, thrombocytopenia and hair loss. To overcome the side... 
Etoposide | Drug delivery | PI3K–AKT | Layered double hydroxide | A549 | PI3K-AKT | APOPTOSIS | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | PI3K INHIBITORS | TUMOR | BIOAVAILABILITY | CHEMOTHERAPY | DELIVERY | NANOPARTICLES | IN-VITRO | DRUGS | GLYCOPROTEIN | Lung Neoplasms - drug therapy | Nanoparticles - chemistry | Humans | Lung Neoplasms - metabolism | Delayed-Action Preparations - chemistry | Lung Neoplasms - pathology | Delayed-Action Preparations - pharmacology | Delayed-Action Preparations - pharmacokinetics | Female | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Etoposide - adverse effects | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Antineoplastic Agents, Phytogenic - chemistry | Xenograft Model Antitumor Assays | Animals | Delayed-Action Preparations - adverse effects | Cell Line, Tumor | Etoposide - chemistry | Mice | Mice, Inbred BALB C | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology | Etoposide - pharmacokinetics | Hydrogen-Ion Concentration | Care and treatment | Hydroxides | Lung cancer, Non-small cell | Cancer | Drugs | Drug delivery systems | Phosphatases | Liver | Lung cancer, Small cell | Hydrogen-ion concentration | Vehicles | Index Medicus | Lungs | In vivo testing | Biocompatibility | Nanostructure | Tumors
Journal Article
Haematologica, ISSN 0390-6078, 11/2017, Volume 102, Issue 12, pp. 2097 - 2103
The standard CHOP therapy for peripheral T-cell lymphoma has resulted in unsatisfactory outcomes and it is still not clear what is the optimal front-line... 
THERAPY | RITUXIMAB | RESISTANCE | ADRIAMYCIN | P-GLYCOPROTEIN EXPRESSION | CHOP PLUS ETOPOSIDE | HEMATOLOGY | TRANSPLANTATION | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Febrile Neutropenia - chemically induced | Humans | Lymphoma, T-Cell, Peripheral - complications | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Vincristine - administration & dosage | Adult | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Etoposide - toxicity | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Vincristine - toxicity | Anemia - chemically induced | Etoposide - administration & dosage | Etoposide - therapeutic use | Treatment Outcome | Thrombocytopenia - chemically induced | Doxorubicin - toxicity | Antineoplastic Combined Chemotherapy Protocols - toxicity | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Cyclophosphamide - toxicity | Prednisone - toxicity | Doxorubicin - adverse effects | Prednisone - therapeutic use | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 15, pp. 3008 - 3016
Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have... 
PHASE-II TRIAL | ETOPOSIDE | IMMUNODEFICIENCY-VIRUS-INFECTION | CYCLOPHOSPHAMIDE | ACTIVE ANTIRETROVIRAL THERAPY | ACUTE LYMPHOBLASTIC-LEUKEMIA | DOXORUBICIN | CHOP | DOSE-ADJUSTED EPOCH | HEMATOLOGY | DECLINING MORBIDITY | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | HIV - physiology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Vincristine - administration & dosage | Adult | Female | Lymphoma, B-Cell - virology | Doxorubicin - administration & dosage | Lymphoma, B-Cell - drug therapy | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Etoposide - adverse effects | Prednisone - adverse effects | Rituximab | Etoposide - administration & dosage | Etoposide - therapeutic use | Treatment Outcome | Disease Progression | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, B-Cell - pathology | Vincristine - therapeutic use | Vincristine - adverse effects | Infusions, Intravenous | Doxorubicin - adverse effects | Prednisone - therapeutic use | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article